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PERSPECTIVES FOR HEALTH TECHNOLOGY ASSESSMENT
PERSPECTIVAS PARA LA EVALUACIÓN DE TECNOLOGÍAS DE SALUD
Marcus Tolentino-Silva1,a

EDITORIAL

An unplanned health care system is like a paper boat carried by a slowly sinking current. In times of disinformation
and excessive distraction, investing in better facts on health technology assessment (HTA) will enable more active
actions rather than reactive to the market dynamics. This paper aims to raise some reflections on HTA in terms of
political context, health technologies and epidemiological priorities.
The perspective of HTA is context dependent, intrinsic to its political and institutional articulation. At the moment, the
paradox is to maintain a specialized structure in the face of economic austerity policies that reduce health resources,
and a scenario of greater interest in raising public funds by the private sector. Particularly in Brazil, HTA will also
have to deal with the gradual shift from a universal health system to a minimum portfolio of services offered by the
private sector1. The public sector will be requested for very expensive technologies, usually by judicial measures.
The precariousness of work relationships will influence HTA workers because they will not have a link and identity
with the health system. Thus, there will be more productive and less reflective HTA processes. The context of greater
dependence on the private market will allow new problems with medical technologies to emerge, such as the opioid
crisis in the United States.
Health technologies will continue to put pressure on health systems. The last decade has been marked by the use
of high cost biological drugs. Others advanced therapy medicinal products are expected to have this momentum
in the coming years2. In addition, there will be greater integration between diagnostic and treatment technologies
(e.g., glucose monitoring devices and insulin pumps) and more information about these products performance.
The HTA specialist will have to keep up with this knowledge and reflect on how the undesirable consequences of
these products will be detected. It is noteworthy that the high technological dependence will make underdeveloped
countries prioritize market needs over those public health.
Underdevelopment induces reliance on essential technologies, such as the need to import basic active ingredients
(e.g. penicillin), and the reversal of science and technology priorities when thinking about health needs. In
consequence, ineffective procedures for poverty-related diseases will persist for many years3. The possibility of
weakening governments and shifting responsibilities to the private sector will increase access inequality and new
inputs will address the epidemiological priorities of developed countries. Mitigating health technology approval
mechanisms will induce HTA to strengthen monitoring and new ways of reimbursement, such as risk-sharing.
Epidemiological challenges often push themselves on society. Going back to the Brazilian scenario, the past decade
was marked the epidemiology of infectious diseases with the emergence of microcephaly associated with the Zika
virus4. Despite it was a disease with little knowledgement, the country responded satisfactorily due to past years
investments in research and development. However, the pandemic increased issues about social justice issues,
like reproductive rights of women. Considering the possibility of further outbreaks and diseases, the answer will
be uncertain because the sustainability of science and technology is out of priority. Accordingly, the HTA specialist
will have to cope with the poorest information to induce health decisions. In the short term we will look at the
health consequences of oil spills on beaches in northeastern Brazil, the increased access to pesticides and the use of
electronic cigarettes. This group of problems will be merged by still persistent issues such as chronic and infectious
diseases, in which they are related to more effective public policies to control risk factors in the population, such
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as known harmful products (eg sugar, cigarettes, and
alcohol) and sanitation.
The weakening scenario of the governments will be
combine with the growth of conflicts of interest. Such
conflicts will make HTA process more arduous, especially
about outcomes measurements and the confidentiality
of clinical trial data. For studies to have faster conclusions,
surrogate and combined outcomes will become more
frequent5. Bias regarding selectivity in reporting outcomes
will be common, considering the fragility of approval
process and the revolving door movement (people with
private interest working in the public sector, and vice
versa). There will also be an increase in qualitative studies
on technology users' perceptions, which will be influenced
by the Hawthorne effect (performance improvement
by observation) and placebo effect (performance
improvement as suggested), compared to a medical
absence scenario.
The past decade has also been marked by new
methodological approaches to assessing the performance

of medical technologies, including indirect comparisons,
comparative effectiveness research, and new analytical
models in cost-effectiveness studies. The HTA specialist
will have to learn the issues of these approaches and how
they will influence decision making6. This is an important
challenge in a scenario of low investment in education.
Training professionals with these skills depends on
scholarships and access to good quality postgraduate
courses. It is worth mentioning the expectation of a larger
number of unconventional databases in terms of structure
and size (big data) and the use of artificial intelligence in
health decisions and in the right of access to services.
In the medium to long term, it is clear that the health
systems we know will sink and change the processes of
HTA. These changes are slow and sometimes difficult
to perceive, as the search for medical care is irregular,
especially in underdeveloped contexts. Further reflection
on these aspects will enable more active behavior by
managers and politics committed to a more equalitarian
and just society.
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